A Phase I Study of Single-centre, Open-label clinical trial to Evaluate HG146 Capsule in the Treatment of Relapsed and Refractory Multiple Myeloma
Latest Information Update: 14 Oct 2024
At a glance
- Drugs HG-146 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors HitGen
- 20 Sep 2023 Status changed from recruiting to discontinued.
- 16 Mar 2022 Planned End Date changed from 12 Jun 2022 to 30 Mar 2023.
- 16 Mar 2022 Planned primary completion date changed from 12 Dec 2021 to 30 Dec 2022.